Expression of osteopontin and HGF/Met in adult soft tissue tumors

被引:26
作者
Bramwell, VHC
Tuck, AB
Wilson, SM
Stitt, LW
Cherian, AK
Rorke, SC
Al-Katib, W
Postenka, CO
Chambers, AF
机构
[1] London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada
[2] London Hlth Sci Ctr, Dept Pathol, London, ON, Canada
关键词
sarcoma; molecular markers; prognosis; Met; osteopontin; hepatocyte growth factor; hepatocyte growth factor receptor;
D O I
10.4161/cbt.4.12.2166
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
There is a need for molecular markers that predict biological behavior of adult soft tissue tumors. Elevated levels of osteopontin (OPN) a transformation-linked protein, have been associated with poor survival in many cancers. OPN induces cell migration in cancer cells, in part through activation of the hepatocyte growth factor (HGF) receptor (Met) and its signaling pathway. Met expression has been associated with a poor prognosis in some sarcomas. In a series of 15 patients with adult soft tissue tumors, we found that mRNA levels of OPN (p = 0.015), Met (p = 0.03) and HGF (p < 0.001) were significantly higher in tumor tissues relative to paired normal tissues. By immunohistochemistry, in tumor tissue from 33 patients, we demonstrated that increased expression of OPN, but not Met protein, was associated with higher stage (p = 0.025) and grade (p = 0.005). We found that increased expression of OPN, but not Met protein, was associated with decreased overall survival (p = 0.008) at five years. This study, which is the first to examine coexpression of these two markers, suggests that OPN may have potential as a prognostic marker in adult soft tissue sarcomas, and further that OPN +/- Met signaling pathways may contribute to their biological behavior.
引用
收藏
页码:1336 / 1341
页数:6
相关论文
共 55 条
[1]
Agrawal D, 2002, J NATL CANCER I, V94, P513
[2]
Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma [J].
Arihiro, K ;
Inai, K .
PATHOLOGY INTERNATIONAL, 2001, 51 (02) :100-106
[3]
Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO
[4]
2-E
[5]
Borden EC, 2003, CLIN CANCER RES, V9, P1941
[6]
IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[7]
Brennan MF, 2001, CANC PRINCIPLES PRAC, P1841
[8]
BROWN LF, 1994, AM J PATHOL, V145, P610
[9]
Osteopontin expression in lung cancer [J].
Chambers, AF ;
Wilson, SM ;
Kerkvliet, N ;
OMalley, FP ;
Harris, JF ;
Casson, AG .
LUNG CANCER, 1996, 15 (03) :311-323
[10]
Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma [J].
Coltella, N ;
Manara, MC ;
Cerisano, V ;
Trusolino, L ;
Di Renzo, MF ;
Scotlandi, K ;
Ferracini, R .
FASEB JOURNAL, 2003, 17 (06) :1162-+